Cardiovascular mortality risk when classified according to eGFR recalculated with cystatin C, as compared with the combination formula
| Evaluated (N) | Reclassified to higher eGFR with cystatin C | Not reclassified | Reclassified to lower eGFR with cystatin C | ||||
| N (%) | HR (95% CI) | N (%) | HR (95% CI) | N (%) | HR (95% CI) | ||
| 889 events | 213 events | ||||||
| eGFRcomb ≥60 | 11 925 | NA | NA | 10 795 (91) | Ref | 1130 (9) | 2.41 (2.08 to 2.80) |
| eGFRcomb ≥60, adj | 11 925 | NA | NA | 10 795 (91) | Ref | 1130 (9) | 1.36 (1.16 to 1.59) |
| 53 events | 862 events | 120 events | |||||
| eGFRcomb 30–59 | 3454 | 218 (6) | 0.81 (0.61 to 1.07) | 2968 (86) | Ref | 268 (8) | 1.75 (1.45 to 2.12) |
| eGFRcomb 30–59, adj | 3454 | 218 (6) | 1.01 (0.76 to 1.34) | 2968 (86) | Ref | 268 (8) | 1.57 (1.29 to 1.91) |
| 42 events | 263 events | 56 events | |||||
| eGFRcomb 20–29 | 804 | 140 (17) | 0.54 (0.39 to 0.75) | 553 (69) | Ref | 111 (14) | 1.05 (0.78 to 1.40) |
| eGFRcomb 20–29, adj | 804 | 140 (17) | 0.67 (0.48 to 0.93) | 553 (69) | Ref | 111 (14) | 0.99 (0.73 to 1.33) |
| 29 events | 327 events | ||||||
| eGFRcomb <20 | 756 | 101 (13) | 0.51 (0.35 to 0.75) | 655 (87) | Ref | NA | NA |
| eGFRcomb <20, adj | 756 | 101 (13) | 0.59 (0.40 to 0.87) | 655 (87) | Ref | NA | NA |
Adj=adjusted for age, gender, Charlson Comorbidity Index, and prior diagnosis of diabetes, obesity, hypertension or cardiovascular disease.
eGFR, estimated glomerular filtration rate; NA, not available.